一分钟看懂
这是一项关于肺癌的I 期 / II 期研究，登记的药物或干预包括Telisotuzumab Adizutecan；Budigalimab；Pembrolizumab；Carboplatin；Pemetrexed；Cisplatin，当前状态为招募中。登记地点显示中国北京、福州、柳州、郑州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Telisotuzumab Adizutecan；Budigalimab；Pembrolizumab；Carboplatin；Pemetrexed；Cisplatin · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Cancer Hospital - Chinese Academy of Medical Sciences /ID# 269715 · 北京
- Fujian Province Cancer Hospital /ID# 269150 · 福州
- Liuzhou People's hospital /ID# 269667 · 柳州
- Henan Cancer Hospital /ID# 269668 · 郑州
- Union Hospital - Tongji Medical College /ID# 272286 · 武汉
- Hunan Province Cancer Hospital /ID# 269679 · 长沙
- Nanjing Drum Tower Hospital /ID# 269762 · 南京
- The First Affiliated Hospital of Nanchang University /ID# 269190 · 南昌
- The First Affiliated Hospital of Xi'an Jiaotong University /ID# 271904 · 西安
- Shanghai Chest Hospital /ID# 269155 · 上海
- Shanghai Pulmonary Hospital /ID# 276397 · 上海
- First Affiliated Hospital of Shanxi Medical University /ID# 276482 · 太原
- Sichuan Cancer Hospital /ID# 269712 · 成都
- West China Hospital of Sichuan University /ID# 270244 · 成都
- Yunnan Province Cancer Hospital /ID# 272331 · 昆明
公开的入选条件
- * Must have histologically documented non-squamous (NSq) non small cell lung carcinoma (NSCLC) that is locally advanced or metastatic will be enrolled into the study.
- * Must have measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1.
- * For Part 1, participants must have had no more than 1 systemic therapy for advanced disease including platinum-based chemotherapy or an immune checkpoint inhibitor (as monotherapy or in combination with chemotherapy), or appropriate targeted therapy for an a
- * For Part 2, participants must have no prior systemic therapy for advanced disease, no known actionable genomic alteration.
- * Must have documented programmed death ligand 1 (PD-L1) status.
- * For Part 2, participant must have evaluable c-Met immunohistochemistry (IHC) result per central testing prior to randomization.
- * Must have adequate organ function.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06772623；登记信息更新于 2026-09-11。